Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Sten Stovall
Ziylo's co-founders established an incubator in Bristol to overcome a lack of lab space and hope their biotech's success will help attract investment there and overcome such hurdles now.
Novo Nordisk has bought UK-based start-up Ziylo in hopes of accelerating development of glucose-responsive insulins, but admits any such products are at least ten years away.
Stephen Gough has kept his connections with Oxford University and will see collaborations between the two expand next month with the opening of the Novo Nordisk Research Centre Oxford. The executive spoke to Scrip.
Flush with IPO funding, AI-focused healthcare technology group Sensyne Health will now ready additional products and find three more NHS trust partnerships. CEO Lord Drayson spoke to Scrip.
Vertex says it will not file data on its cystic fibrosis drug Symkevi (tezacaftor/ivacaftor) until the UK's NICE changes the way it assesses drugs.
Long-term top-line market forecasts for Novo Nordisk are heavily reliant on its GLP-1 portfolio's potential - so pricing uncertainties, especially in the US, can unnerve sentiment, as seen when it reported Q2 results.